Barclays Reaffirms Their Hold Rating on Tvardi Therapeutics (TVRD)

Tip Ranks
2025.11.14 09:06

Barclays analyst Etzer Darout maintained a Hold rating on Tvardi Therapeutics with a $5.00 price target. Darout, who covers the Healthcare sector, has an average return of 23.7% and a 54.75% success rate. The general analyst consensus for Tvardi Therapeutics is a Moderate Buy with a $16.00 average price target.

Barclays analyst Etzer Darout maintained a Hold rating on Tvardi Therapeutics today and set a price target of $5.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Darout covers the Healthcare sector, focusing on stocks such as Terns Pharmaceuticals, Exelixis, and Arvinas Holding Company. According to TipRanks, Darout has an average return of 23.7% and a 54.75% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Tvardi Therapeutics with a $16.00 average price target.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.